Forecast: Basic Pharmaceutical Products Turnover in the Netherlands

The basic pharmaceutical products turnover in the Netherlands has displayed significant growth from 2013 to 2023, rising from 130.3 million euros in 2013 to 746.5 million euros in 2023. Major milestones include marked increments in 2019 (32.38%), 2020 (59.33%), and 2021 (34.87%). The last two years showed continued positive trends with 26.34% and 20.75% growth rates in 2022 and 2023, respectively. The Compound Annual Growth Rate (CAGR) from 2018 to 2023 was 34.12%, reflecting robust and accelerating industry performance.

Looking ahead, the forecast from 2024 to 2028 indicates a continued upward trajectory, with turnover expected to reach 1380 million euros by 2028. The projected five-year CAGR is 9.54%, indicating sustained, though slower, growth compared to the past five years.

Future trends to watch include:

• Impact of regulatory changes on market dynamics and new product introductions.
• The role of technological advancements in R&D and manufacturing efficiencies.
• Expansion into emerging markets and the effect of global economic conditions on pharmaceutical demand.
• Strategic partnerships and mergers or acquisitions influencing market consolidation.